

PROGRESSIVE'S EVENING STROLL

DATE: 06 February, 2026

Market Snapshot:

Heightened volatility was seen in today's trade as the Index compounded its losses after the MPC decided to keep the rate unchanged. However, select heavyweight stocks took the lead and supported the Index in recouping its losses. But the Index struggled to sustain at higher levels and wiped out all its recovery gains. A sharp uptick across the board in the last session pushed the Index higher to settle the trade at 25,693.70 with gains of 50.90 points. Among the sectors, FMCG was the top performer, followed by Realty, while the Capital Market Index and IT were the laggards. Despite a sharp recovery, Mid and Smallcaps underperformed Nifty50.

HOW THE DAY TRENDED



INDICES			
Index	Close	Points	%Chg.
Sensex	83580.40	266.47	0.32
Nifty50	25693.70	50.90	0.20
Nifty Midcap 100	59502.70	(14.40)	(0.02)
Nifty Small Cap 100	16938.65	(45.25)	(0.27)

SECTORAL GAINERS / LOSERS			
Sectors	Close	Points	%Chg.
NIFTY FMCG	51882.75	1151.10	2.27
NIFTY REALTY	824.85	5.15	0.63
NIFTY CAPITAL MKT	4717.50	(48.35)	(1.01)
NIFTY IT	35611.05	(532.25)	(1.47)

NIFTY TOP GAINERS / LOSERS					
Gainers	CMP (Rs)	%Chg.	Losers	CMP (Rs)	%Chg.
ITC	325.80	5.03	HDFC LIFE	703.50	(2.39)
KOTAK BANK	422.35	3.33	TCS	2941.60	(1.67)
HUL	2424.20	2.96	TECH MAHINDRA	1619.90	(1.60)
BHARTI AIRTEL	2038.40	2.31	BAJAJ AUTO	9518.50	(1.33)

INDICES LEVELS FOR February 09, 2026

Nifty (future)	
Resistance	25880
Support	25560

Bank Nifty (future)	
Resistance	60600
Support	59820



PROGRESSIVE'S EVENING STROLL

DATE: 06 February, 2026

KEY TAKEAWAYS OF THE DAY

◆ **Blackstone gets India's central bank nod to buy Federal Bank stake:**

The Indian central bank has approved private equity firm Blackstone's acquisition of up to a 9.99% stake in Federal Bank. The deal, which would make Blackstone the largest shareholder in the bank, adds to the growing list of large investments by marquee investors in the financial services sector in India. The private equity firm's investment will be done through a Singapore-based affiliate, with the agreement giving Blackstone the right to nominate a non-executive director to the lender's board.

◆ **UltraTech Cement commissions additional 2.7 MTPA grinding capacity in Aligarh:**

The company announced the commissioning of an additional grinding capacity of 2.7MTPA at its Aligarh unit in Uttar Pradesh. With this commissioning, the total cement grinding capacity of the Aligarh unit now stands at 4.0MTPA, increasing the company's capacity in Uttar Pradesh to 13.1MTPA. With this addition, UltraTech's total domestic grey cement manufacturing capacity stands at 191.36MTPA. Along with its overseas capacity of 5.4MTPA, the company's global capacity now stands at 196.76MTPA.

◆ **Strides Pharma's unit in New York classified as voluntary action indicated by USFDA:**

Strides Pharma Science said its arm Strides Pharma Inc (SPI) has received establishment inspection report from the US health regulator for its formulation's unit at Chestnut Ridge in New York classifying the facility as voluntary action indicated. Based on SPI's response to the Form 483 that was issued at the conclusion of the inspection, the USFDA has classified the inspection outcome as VAI (voluntary action indicated). The EIR states that the inspection has been closed.

◆ **Oberoi Realty wins bid for 11-acre land in Mumbai for Rs5,400cr:**

Oberoi Realty has emerged as the highest bidder for an 11-acre land in Mumbai with a bid value of Rs5,400cr. The company said it had participated in the bids invited by Railway Land Development Authority (RLDA) for the grant of a lease for the development of 45,371sq.mt. (about 11 acres) of railway land in Bandra East for 99 years, with Floor Space Index (FSI) potential of 19.50lakh sq. ft. The financial bids were opened by RLDA.

◆ **Alembic to skip first wave of global Semaglutide launches, eyes India:**

Alembic Pharmaceuticals said it will miss the first wave of global generic semaglutide launches but is exploring partnerships for a faster entry into the Indian market. The company indicated that it is late into the Semaglutide market internationally at least for the first wave. But if there is opportunity it will be there during the second phase.

Source: Media Reports



DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,
122-124, Laxmi Plaza, Laxmi Indl Estate,
New Link Rd, Andheri West,
Mumbai—400053, Maharashtra
www.progressiveshares.com | Contact No.:022-40777500.

Compliance Officer:

Ms. Mamatha Poojari,
Email: compliance@progressiveshares.com,
Contact No.:022-40777500.

Grievance Officer:

Email: grievancecell@progressiveshares.com

